Details of the Drug

General Information of Drug (ID: DM9AV14)

Drug Name

TBA-354

Synonyms

1257426-19-9; TBA354; (s)-2-nitro-6-((6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methoxy)-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine; UNII-911T37M2WY; TBA 354; 911T37M2WY; (6S)-2-Nitro-6-({6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl}methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]-3-pyridyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; SCHEMBL508426; CHEMBL1630563; EX-A526; MFCD28009369; ZINC66252280; AKOS025404945; CS-3576; SB17064; NCGC00390647-01; HY-12485; B5935; Q27896161; ((6S)-6-((6-(4-(Trifluoromethoxy)phenyl)-3-pyridyl)methoxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazin-2-yl)azinic acid; (6S)-6,7-Dihydro-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]-3-pyridinyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; (sn31354((S)-2-Nitro-6-((6-(4-trifluoromethoxy)phenyl)pyridine-3-yl)methoxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine)); 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]-3-pyridinyl]methoxy]-, (6S)-

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H15F3N4O5
Canonical SMILES: C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CN=C(C=C3)C4=CC=C(C=C4)OC(F)(F)F
InChI: 1S/C19H15F3N4O5/c20-19(21,22)31-14-4-2-13(3-5-14)16-6-1-12(7-23-16)10-29-15-8-25-9-17(26(27)28)24-18(25)30-11-15/h1-7,9,15H,8,10-11H2/t15-/m0/s1
InChIKey: ZXSGSFMORAILEY-HNNXBMFYSA-N

Cross-matching ID

PubChem CID: 49836057
CAS Number: 1257426-19-9
TTD ID: D9Q5UP

References

1	ClinicalTrials.gov (NCT02288481) A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects. U.S. National Institutes of Health.